Doing it All - How Families are Reshaping Rare Disease Research

7Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The face of rare disease drug discovery and development is changing right before our eyes. The outliers of the past were the plucky parents who summoned up the courage to try to treat their children against all odds. Think of the rare disease focused movies ‘Lorenzo’s Oil’ and ‘Extraordinary Measures’ but now accelerated to develop treatments even quicker. Parents, patient advocates and their collaborators are now capable of doing it all themselves. We think this will have profound implications for everyone from the incumbent rare disease foundations that have held sway for decades to the multibillion dollar rare disease market, BioPharma companies, VCs and angel investors that inhabit this space. The repercussions of this disruption will no doubt impact healthcare in general and ultimately influence how we develop treatments for major diseases as well. We present several lines of evidence for our viewpoint from our personal experiences interacting with many rare disease families and patient advocates in recent years.

Cite

CITATION STYLE

APA

Ekins, S., & Perlstein, E. O. (2018, October 1). Doing it All - How Families are Reshaping Rare Disease Research. Pharmaceutical Research. Springer New York LLC. https://doi.org/10.1007/s11095-018-2481-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free